Akero Therapeutics, Inc., a biotechnology company focusing on metabolic dysregulation diseases, provided updates regarding ...

It’s been a busy week in remote work discourse. It kicked off with Monday’s Return to In-Person Work memorandum, issued by ...

Akero Therapeutics (AKRO) released preliminary topline week 96 results from SYMMETRY, a Phase 2b study evaluating the efficacy and safety of ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

US clinical-stage liver disease focused biotech Akero Therapeutics saw its shares almost double to $51.71 yesterday, after it ...

Symmetry Panoramic US Equity Fund earns a Below ... This strategy has also tilted toward low-quality stocks, companies with higher financial leverage and lower profitability over peers in recent ...

Trustco Group Holdings announced on Tuesday that its Board of Directors is exploring options to delist from its current stock exchanges, including the Johannesburg Stock Exchange (JSE), the Namibian ...

Akero stock soars 106% in a week following initial positive top line 96-week data from a mid-stage MASH study of its lead ...

Akero Therapeutics reports a 39% improvement in cirrhosis patients using EFX. See why AKRO stock is soaring with the ...

Canaccord Genuity adjusted its outlook on Akero Therapeutics (NASDAQ: NASDAQ:AKRO) shares, raising the price target to $73 ...

Investing.com -- Shares of Akero Therapeutics, Inc. (Nasdaq: NASDAQ: AKRO) soared 92% following the release of preliminary topline results from its Phase 2b SYMMETRY study, which showed a ...